JP Morgan Chase
LXEO icon

JP Morgan Chase’s Lexeo Therapeutics LXEO Stock Holding History

JP Morgan Chase’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Buy
96,290
+3,127
+3% +$16.9K ﹤0.01% 5169
2026
Q1 		$491K Buy
93,163
+63,302
+212% +$449K ﹤0.01% 5046
2025
Q4 		$297K Buy
29,861
+15,502
+108% +$141K ﹤0.01% 5321
2025
Q3 		$95.3K Buy
14,359
+609
+4% +$2.94K ﹤0.01% 5930
2025
Q2 		$55.3K Sell
13,750
-30
-0.2% -$99 ﹤0.01% 5888
2025
Q1 		$47.8K Buy
13,780
+409
+3% +$1.81K ﹤0.01% 5898
2024
Q4 		$88K Buy
13,371
+3,093
+30% +$24.4K ﹤0.01% 5802
2024
Q3 		$92.9K Buy
10,278
+5,915
+136% +$70.5K ﹤0.01% 5734
2024
Q2 		$70K Sell
4,363
-1,590
-27% -$23.1K ﹤0.01% 5708
2024
Q1 		$93.3K Buy
5,953
+5,841
+5,215% +$91.3K ﹤0.01% 5702
2023
Q4 		$1.5K Buy
+112
New +$1.39K ﹤0.01% 6769

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JP Morgan Chase's LXEO Position: Q2 2026 in Review

JP Morgan Chase increased its Lexeo Therapeutics (LXEO) stake by 3.4% in Q2 2026, buying an estimated $16.9K and bringing the position to 96,290 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #5169.

JP Morgan Chase first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $491K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • JP Morgan Chase held 96,290 shares of Lexeo Therapeutics worth $463K as of Q2 2026.
  • JP Morgan Chase bought 3,127 Lexeo Therapeutics shares in Q2 2026, an estimated $16.9K.
  • Lexeo Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5169 holding.
  • JP Morgan Chase first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • JP Morgan Chase's Lexeo Therapeutics position peaked at $491K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.